Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reported $1.76 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.72 by $0.04. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $1.30 earnings per share. The company’s quarterly revenue was up 76.6% on a year-over-year basis. Analysts expect that Valeant Pharmaceuticals Intl will post $8.75 EPS for the current fiscal year. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) net profit margin is -13.10% and weekly performance is -5.62%. On last trading day company shares ended up $126.63. Analysts mean target price for the company is $52.38. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) distance from 50-day simple moving average (SMA50) is -2.03%.
On 2 JUNE Alkermes Plc (NASDAQ:ALKS) announced the initiation of the second phase 2 study of ALKS 3831, a novel, oral, broad-spectrum antipsychotic medicine in development for schizophrenia. The randomized, double-blind, active-controlled study will assess ALKS 3831’s efficacy, safety and tolerability in treating schizophrenia in patients with co-occurring alcohol use disorder, compared to olanzapine, an approved and widely used atypical antipsychotic medicine. Alkermes Plc (NASDAQ:ALKS) shares fell -0.12% in last trading session and ended the day on $48.32. ALKS Gross Margin is 69.30% and its return on assets is -0.40%. Alkermes Plc (NASDAQ:ALKS) quarterly performance is 5.04%.
On 4 JUNE Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.05) by $0.03. Analysts expect that Acura Pharmaceuticals will post $-0.16 EPS for the current fiscal year. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) shares moved down -4.81% in last trading session and was closed at $0.990, while trading in range of $0.98 – $1.06. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) year to date (YTD) performance is -40.72%.
On 27 MAY Petmed Express Inc (NASDAQ:PETS) reported a mixed fourth-quarter fiscal 2014 with better-than-expected earnings per share (EPS) and a revenue miss. This nationwide pet pharmacy presently carries a Zacks Rank #3 (Hold). Petmed Express Inc (NASDAQ:PETS) ended the last trading day at $13.80. Company weekly volatility is calculated as 2.22% and price to cash ratio as 8.24. Petmed Express Inc (NASDAQ:PETS) showed a positive weekly performance of 3.53%.
On 5 JUNE Flamel Technologies S.A. (ADR) (NASDAQ:FLML) announced that it has been informed by the Active Pharmaceutical Ingredient (API) supplier for its second New Drug Application (NDA) that the Food and Drug Administration (FDA) has now classified its facility as acceptable. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) weekly performance is 7.47%. On last trading day company shares ended up $12.09. Analysts mean target price for the company is $20.95. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) distance from 50-day simple moving average (SMA50) is 3.58%.